Feinstein Institutes Study Examines Clinical Benefit of Anifrolumab on Lupus
November 11, 2019
November 11, 2019
MANHASSET, New York, Nov. 11 -- Feinstein Institute for Medical Research issued the following news release:
The Feinstein Institutes for Medical Research Professor Richard Furie, MD, will publish and present data describing the clinical benefit of anifrolumab for patients with lupus in Lancet Rheumatology and at the American College of Rheumatology's Annual Scientific Meeting.
Anifrolumab is a monoclonal antibody designed for the treatment of systemic lupus erythematosu . . .
The Feinstein Institutes for Medical Research Professor Richard Furie, MD, will publish and present data describing the clinical benefit of anifrolumab for patients with lupus in Lancet Rheumatology and at the American College of Rheumatology's Annual Scientific Meeting.
Anifrolumab is a monoclonal antibody designed for the treatment of systemic lupus erythematosu . . .